Immunogenicity and safety of an E. coli-produced human papillomavirus vaccine: A phase 2 controlled trial
Premalignant and malignant lesions of the cervix and other sites related to the human papillomavirus (HPV) infection pose a significant health burden worldwide, especially in developing countries. Although prophylactic HPV ...
Oct 18, 2023
0
0